---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107300"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:55:21.031814+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyverna Q2 net loss $42.1M, cash $211.7M; advances KYV-101 in SPS and MG

## Summary
- Net loss $42.1M ($0.97/share) vs $28.8M in Q2 2024; R&D expenses rose to $35.8M from $27.3M.
- Cash and equivalents $211.7M as of June 30, 2025, funding operations into 2027.
- Phase 2 SPS registrational trial enrollment complete; topline data and BLA filing expected 1H 2026.
- Phase 3 MG trial (~60 patients) enrollment to start by year-end 2025; interim Phase 2 data in Q4 2025.
- Marc Grasso appointed CFO in June 2025; KYV-102 IND filing expected Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-107300
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/0000950170-25-107300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/kytx-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107300
- JSON: https://secwatch.observer/filing/0000950170-25-107300.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.